PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project aimed at improving management of side effects caused by poly ADP ribose polymerase inhibitors (PARPi) in patients with metastatic castration-resistant prostate cancer (mCRPC). The research is supported by Pfizer Global Medical Grants and Partnerships.
PARPi use has been linked to hematologic toxicities, particularly anemia, which affects roughly 25% of patients soon after starting treatment. These toxicities often lead to changes in dosing, interruptions, or discontinuation of therapy, creating challenges for patients—many of whom are older, have reduced bone strength, or face other health issues. With the growing use of PARPi and its combination with other therapies, this research aims to better manage adverse effects and improve outcomes for patients.
“The aim of this research is to advance our understanding and ability to reduce adverse effects from PARPi alone or in combination with other treatments for patients with prostate cancer,” said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. “Congratulations to this remarkable investigator. This work will enhance our understanding of how to better care for individuals with prostate cancer.”
The selected project, led by Dr. David Link at the Siteman Cancer Center, will examine the impact of germline BRCA1/2 mutations on PARPi-induced anemia. The findings could lead to improved treatment strategies for patients experiencing these side effects.
Pfizer praised the initiative and its potential to reduce healthcare disparities. “We are really pleased to support this important research and to collaborate with the National Comprehensive Cancer Network,” said Maureen Doyle-Scharff, PhD, Head of Global Medical Grants and Partnerships at Pfizer. “This work accelerates our efforts to improve health outcomes for prostate cancer patients.”
The project underwent a rigorous review by a committee of oncologists from NCCN Member Institutions. Completion of the research is expected within two years.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.